A Phase IV, Open-label, Single Arm, Multicentre Trial of Grazoprevir/Elbasvir for Genotype 1 or 4 in People With Chronic Hepatitis C Virus Infection and Recent Injecting Drug Use

Trial Profile

A Phase IV, Open-label, Single Arm, Multicentre Trial of Grazoprevir/Elbasvir for Genotype 1 or 4 in People With Chronic Hepatitis C Virus Infection and Recent Injecting Drug Use

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 26 Jul 2017

At a glance

  • Drugs Elbasvir/grazoprevir (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Acronyms DARLO-C
  • Most Recent Events

    • 14 Jun 2017 Planned End Date changed from 1 Dec 2020 to 1 Oct 2021.
    • 14 Jun 2017 Planned primary completion date changed from 1 Dec 2020 to 1 Apr 2021.
    • 14 Jun 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top